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The  ferulic  and  gallic  acid related  compounds  from  natural  origin  were  studied  against  xanthine  oxidase
and cyclooxygenase-2  along  with  their  anti-inﬂammatory  activity.  The  compounds  gallic  acid,  ferulic
acid, caffeic  acid  and  p-coumaric  acid  revealed  promising  anti-inﬂammatory  activity  (30–40%  TNF-
and  60–75%  IL-6  inhibitory  activity  at 10 M). Bioavailability  of  compounds  were  checked  by in vitro
cytotoxicity  using  CCK-8  cell  lines  and conﬁrmed  to  be  nontoxic,  but found  toxic  at  higher  concentration
(50  M).  Gallic,  ferulic,  caffeic  acid  was  demonstrated  potential  dual inhibition  toward  xanthine  oxidaseallic acid
anthine oxidase
yclooxygenase
AR
out
and  cyclooxygenase-2  as  calculated  by  IC50:  68,  70.2,  and  65  g/ml  (xanthine  oxidase)  and 68.5,  65.2,
and  62.5  g/ml  (cyclooxygenase-2),  respectively.  The  structure  activity  relationship  and  in silico  drug
relevant  properties  (HBD,  HBA,  PSA,  c Log P, ionization  potential,  molecular  weight,  EHOMO and  ELUMO)
further  conﬁrmed  that  the  compounds  were  potential  candidates  for future  drug  discovery  study,  which
was  expected  for further  rational  drug  design  against  xanthine  oxidase  and  cyclooxygenase.
©  2015  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
Gouty arthritis is a well known disease with an abrupt attack
ausing extreme pain in and around the joints due to activi-
ies occurred by xanthine oxidase (Mohapatra et al., 2015). Gout
s nearly always associated with chronic hyperuricemia, a long-
asting abnormally high concentration of uric acid (hyperuricemia)
n the blood. The higher levels of uric acid can reach a point where
ric acid crystals (monosodium urate) are put differently and this
yperuricemia results in the deposition of crystals of sodium urate
n tissues, especially in kidneys and joints (Bardin, 2004; Choi and
urhan, 2005). This process generates oxygen metabolites, which
amage tissue, resulting in the release of lysosomal enzymes that
nduce an inﬂammatory response. This will lead to local decrease
f pH which further causes more deposition of urate crystals (Nuki
nd Simkin, 2006). The diagnosis of gout is based on the presence
f monosodium urate crystals in the synovial ﬂuid (Martinon and
limcher, 2006). This deposition will exacerbate leading to recur-
ent episodes of acute arthritis, the classic manifestation of gout.
eanwhile, controlling the uric acid level in the blood is still the
ain target particularly in the management of the chronic attacks
Mandell, 2002; Dincer et al., 2002). Xanthine oxidase (XO) has
∗ Corresponding author.
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102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editoraa major role in the uric acid production as XO is responsible for
catalyzing the oxidation of hypoxanthine to form xanthine and
ﬁnally to uric acid. Thus, this enzyme coordinates the reaction
and produces uric acid from its precursors (Nile et al., 2013; Li
et al., 2013). Similarly, certain enzymes such as cyclooxygenase-
2 (COX-2) contributes its role in the gouty inﬂammation, though it
heightened expressions in the presence of the accumulated MSU
crystals, which in turn enhances the production of inﬂammatory
prostaglandins leading to the increased production of IL-1. Thus,
COX-2 plays a major role in arousing the inﬂammatory responses
and thus taking part in the advancement of the acute inﬂamma-
tion in the gouty arthritis patients (Pouliot et al., 1998; Mohapatra
et al., 2015). There are certain measures taken in order to treat the
disease by using non-steroidal anti-inﬂammatory drugs (NSAID),
colchicine or gluco corticoids. NSAID are the class of drugs which
causes COX-2 inhibition whereas colchicine is an antimycotic alka-
loid that apart from disturbing the microtubule polymerization, it
also inhibits the inﬂammation by preventing the IL-1 processing
which was  stimulated by the MSU  crystals (Martinon et al., 2006;
Ricciotti and FitzGerald, 2011). Examples of such drugs are allo-
purinol, probenecid and sulﬁnpyrazone (Mandell, 2002; Aggarwal
et al., 2011). Modern medicines from natural products have little
to offer for alleviation of gout, oxidative and inﬂammatory activ-
ity. There is an urgent need to discover compounds with xanthine
oxidase inhibitory activities but devoid of the undesirable effects of
allopurinol. One potential source of such compounds is medicinal
 Ltda. All rights reserved.
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aterials of plant origin which is used to treat conditions similar
o gouty arthritis (Nile and Park, 2014a,b). Phenolics and ﬂavonoids
re considered important components in the human diet because
f their beneﬁcial effects on human health. The phenolics and
avonoids are naturally occurring compounds that are constantly
istributed in various foods, fruit juices and beverages from plant
rigin and display many bioactive and therapeutic properties, such
s antioxidant, anticancer, antiviral, anti-inﬂammatory, and car-
iac protective effects (Proestos et al., 2005; Nile and Park, 2014c).
ost of the therapeutic properties of phenolics and ﬂavonoids have
een demonstrated to have potent antioxidant, anti-inﬂammatory
nd enzyme inhibition properties. Several phenolics and ﬂavonoids
ave been described as inhibitors of the xanthine oxidase (XO)
nzyme, similar to allopurinol in the treatment of gout (Bandgar
t al., 2009; Nile and Park, 2013), for this reason, research into
erulic acid seems promising. Thus, the aim of this study is to
nvestigate the potency of naturally occurring ferulic acid related
ompounds as xanthine oxidase and cyclooxygenase-2 inhibitors
long with the properties like anti-inﬂammatory activity, struc-
ure activity relationship (SAR) and in silico drug relevant properties
ere studied.
aterials and methods
hemicals
Xanthine oxidase, xanthine, allopurinol, myricetin, and iso-
uercetin were purchased from Sigma Chemical (Seoul, Korea).
erulic acid (2), gallic acid (6), and their esters were supplied by
i-Media Laboratories, Mumbai, India. Caffeic acid (3), sinapic acid
4), p-coumaric acid (1) procured from Sigma–Aldrich, Mumbai,
ndia. Cyclooxygenase ﬂuorescent inhibitor screening assay kit was
btained from Cayman Chemical Company (Ann Arbor, MI,  USA).
ovine milk xanthine oxidase procured from (grade 1, ammonium
ulfate suspension) Sigma–Aldrich, Mumbai, India.
CO2HR1
HO
R2
1 R1=R 2=H
2 R1=OCH3; R 2=H
3 R1=OH; R2=H
4 R1=R 2=OCH 3
CO2CH 3
CO2R
H3CO
HO
5
HO
HO
OH
6 R=H
7 R=CH3
8 R=(CH2)2CH3
9 R=(CH2)11 CH3
10 R=(CH2)17 CH3nti-inﬂammatory and cytotoxicity assay
Pro-inﬂammatory cytokine production by lipopolysaccharide
LPS) in THP-1 cells was measured according to the methodrmacognosia 26 (2016) 50–55 51
described by Bandgar et al. (2009). During assay, THP-1 cells were
cultured with penicillin and streptomycin (100 U/ml) and inocu-
lated with 10% fetal bovine serum (FBS, JRH) in RPMI 1640 culture
medium (Gibco BRL, Pasley, UK). Cells were differentiated with
phorbol myristate acetate (PMA, Sigma). Following cell plating,
the test compounds (10 M)  in 0.5% DMSO was  poured to each
well and the plate were incubated for 30 min  at 37 ◦C. Finally, LPS
(Escherichia coli 0127:B8, Sigma Chemical Co., St. Louis, MO)  was
added, at a ﬁnal concentration of 1 g/ml in each well. Plates were
further incubated at 37 ◦C for 24 h in 5% CO2. After incubation,
supernatants were harvested, and assayed for TNF- and IL-6 by
ELISA as described by the manufacturer (BD Biosciences, India). The
cells were simultaneously evaluated for cytotoxicity using CCK-8
from Dojindo Laboratories. Percent inhibition of cytokine release
compared to the control was  calculated. In this the cytotoxicity was
checked at lower, optimum and higher concentration (10, 25 and
50 M),  50% inhibitory concentration (IC50) values were calculated
by a nonlinear regression method (Bandgar and Gawande, 2010;
Nile and Khobragade, 2011).
In silico pharmacological property and SAR study
The pharmacological properties of the compounds, such as
molecular weight, c Log P and quantum chemical descriptors such
as EHOMO (Energy of highest occupied molecular orbital) and ELUMO
(energy of lowest unoccupied molecular orbital) of the synthesized
compounds were calculated using a BioMed CaChe 6.1 (FujiSuit
Ltd), a computer aided molecular design modeling tool for windows
98/20000/XP operating system. Other parameters such as HBA
(hydrogen bond acceptor), HBD (hydrogen bond donor), molecular
PSA (polar surface area), drug score and drug likeness of the com-
pounds were also studied using online Osiris property explorer for
drug bioavailability of chemical compounds. Since compounds are
considered for oral delivery, they were also assessed for toxicity
using in silico ADME prediction methods (Bandgar and Gawande,
2010; Nile and Khobragade, 2011).
XO inhibitory activity
Xanthine oxidase (XO) activity was  assayed spectrophotomet-
rically by measuring the uric acid formation at 290 nm using
a UV-visible spectrophotometer at 25 ◦C. The reaction mixture
contained 50 mM potassium phosphate buffer (pH 7.6), 75 M xan-
thine and 0.08 units of XO. Inhibition of XO activity of individual
isolated phenolics from maize (1.5 ml,  2 mM), was measured by fol-
lowing the decrease in the uric acid formation at 293 nM at 25 ◦C.
The enzyme was  pre incubated for 5 min, with test compound,
dissolved in DMSO (1%, v/v), and the reaction was started by the
addition of xanthine. Final concentration of DMSO (1%, v/v) did
not interfere with the enzyme activity. The XO kinetic study was
carried out using screening of ten ferulic acid related compounds
(10, 25, 50 and 100 g/ml) comparing with allopurinol (10, 25, 50
and 100 g/ml) as positive control. All the experiments were per-
formed in triplicates and IC50 values were expressed as means of
three experiments (Nile et al., 2013; Nile and Park, 2014a).
COX-2 inhibitory activity
Cayman’s COX ﬂuorescent inhibitor screening assay pro-
vides a convenient ﬂuorescent-based method for screening both
ovine COX-1 and human recombinant COX-2 for isozyme-speciﬁc
inhibitors. The assay utilizes the peroxidase component of COX.
The reaction between prostaglandin- G2  and 10-acetyl-3, 7-
dihydroxyphenoxazine produces the highly ﬂuorescent compound
resoruﬁn. Resoruﬁn ﬂuorescence can be easily analyzed with an
excitation wavelength of 540 nm and an emission wavelength of
52 S.H. Nile et al. / Revista Brasileira de Fa
Table 1
Anti-inﬂammatory activity against TNF- and IL-6.
Samples % Inhibition at 10 M
TNF- IL-6 Toxicity
10 M 25 M 50 M
p-Coumaric acid 30 60 0 1.3 3.2
Ferulic acid 40 72 0 1.5 4
Caffeic acid 35 68 0 1.6 3.5
Sinapic acid 23 56 0 2.1 4.5
Alkyl ferulates 20 40 0 2.4 5
Gallic acid 48 75 0 1.6 3.5
Methyl gallate 16 30 0.4 3 8
Propyl gallate 18 35 0 2 5
Lauryl gallate 20 25 0.5 4 8
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aStearyl gallate 15 20 0.4 2 7
Dexamethasone 60 92 0 0 3
95 nm.  The COX-2 assay consisted of a 200-l reaction mixture
ontaining 150 l assay buffer, 10 l heme, 10 l COX-2, 10 l ﬂuo-
ometric substrate, and 10 l of ten ferulic acid related compounds
25, 50, 100 g/ml) The reactions were initiated by quickly adding
0 l AA, then incubating for 5 min  at 37 ◦C temperature. Dup-697
as used as a positive control. All the experiments were performed
n triplicates and IC50 values were expressed as means of three
xperiments (Li et al., 2013; Mohapatra et al., 2015).
tatistical analysis
All data are expressed as mean ± SD of triplicate experiments.
esults and discussion
nti-inﬂammatory and cytotoxicity assay
All ten ferulic acid related compounds were evaluated for anti-
nﬂammatory activity by TNF- and IL-6 inhibition assays. Not all
f the compounds showed a promising TNF- inhibitory activ-
ty except gallic acid, ferulic acid, caffeic acid and p-coumaric
cid up to 30–40% at 10 M concentrations, also a promising IL-6
nhibitory activity was shown by same compounds that is by gal-
ic acid, ferulic acid, caffeic acid and p-coumaric acid up to 60–75%
nhibition at 10 M concentration. As compared to the standard
examethasone, the activity results are revealed to be compara-
le as summarized in Table 1. Most of the compounds did not
how signiﬁcant cytotoxicity at 10 M concentration except lauryl
allate, methyl gallate and stearyl gallate at very negligible level
ut at higher concentrations many of the compounds revealed cell
oxicity. The results presented for ferulic acid related compounds
evealed excellent anti-inﬂammatory activities as compared to
examethasone, a known anti-inﬂammatory agent. It is known
hat during inﬂammation and associated processes, there is an
ncreased production of superoxide ions. It may  be possible that
he inhibition of superoxide generation in peritoneal macrophages
s related to the anti-inﬂammatory activity of ferulic acid related
ompounds (Nile and Khobragade, 2011; Nile and Park, 2014d).
ro-inﬂammatory cytokines such as TNF-, and IL-6 are produced
nd play critical roles in the inﬂammation processes. Among these
ro-inﬂammatory cytokines, TNF- has been highlighted recently
s a main mediator in the inﬂammatory diseases mechanism
Maxiaad et al., 2011). High levels of pro-inﬂammatory cytokines,
ncluding TNF, have been detected in psoriatic skin lesions and
oints of patients with the inﬂammatory disease (Mease, 2002).
NF- may  have a signiﬁcant role in pathogenesis of several inﬂam-
atory diseases, such as psoriatic arthritis, juvenile rheumatoid
rthritis, and Crohn’s disease. Decrease in the TNF- and an IL-6rmacognosia 26 (2016) 50–55
level by these compounds suggests that it may  be useful in a vari-
ety of inﬂammatory conditions (Ellerin et al., 2003; Kuek et al.,
2007).
In silico pharmacological property and SAR study
To qualify the compound as a drug candidate, it is analyzed
by the parameters set by Lipinski’s rule of ﬁve using Osiris prop-
erty explorer. The c Log P is the important physiochemical property
indicating the lipophilicity and the ability of molecule to cross
the various biological membranes. According to Lipinski’s rule of
ﬁve the c Log P value below 5 is feasible for a compound to be a
future drug. The all ten ferulic acid related compounds showed a
marginal lipophilicity within the range of 4.0–5.0. The molecular
weight property of the compound is related to its in vivo adminis-
tration. All the ferulic acid related compounds have the molecular
weight within the acceptable range, that is, 400–500. The com-
pounds showed the HBA below 10 and HBD below 5, which is
also within the limit set by Lipinski’s rule. The polar surface area
(PSA) > 140 A2 is thought to have low oral bioavailability, which
is also revealed within the range for these compounds (Table 2).
Interestingly the compounds also presented a better drug likeness
values. Overall, the compounds ferulic acid, gallic acid, caffeic acid
and sinapic acid showed a good drug score, calculated by combin-
ing all parameters. Drug toxicity is a factor of great importance for
a potential commercial drug, since a signiﬁcant number of drugs
are disapproved in clinical trials based on their high toxicity proﬁle
(Bandgar et al., 2009; Bandgar and Gawande, 2010). The toxicity of
the compounds is calculated in terms of mutagenicity, tumorigenic,
reproductively effective and irritant. All the compounds were con-
ﬁrmed as non-mutagenic and therefore were biologically safe for
intake.
XO inhibition by ferulic acid related compounds
The experimental evidence indicates that, all the ten ferulic acid
related compounds under this study showed a good to excellent
activity proﬁle toward inhibition of xanthine oxidase inhibitory
activity and formation of hydroperoxide. All of the ten ferulic acid
related compounds demonstrated XO-inhibiting activity among
which ferulic acid, gallic acid, caffeic acid, p-coumaric acid, alkyl
gallate, and methyl gallate, showed an inhibition >50% at 100 g/ml
(Fig. 1). Flavonoids and phenolics are well known antioxidants and
attract a signiﬁcant curiosity and scientiﬁc demand by research sci-
entist for utilization as possible therapeutic agents against various
disorders and diseases mediated by active free radicals (Nile and
Park, 2013, 2014b). Phenolics and ﬂavonoids may acts as potent
inhibitors against the metabolic enzymes such as cyclooxygenase,
xanthine oxidase and lipooxygenase (Hoorn et al., 2002). Thus,
the phenolic constituents may  play an essential role in the inhi-
bition of XO and these XO inhibitors and uricosuric agents are
commonly used against the treatment and curing of inﬂammatory
diseases and gouty arthritis. So the drug allopurinol is the drug
of choice against XO activity; however it has serious side effects
(Nile and Park, 2013, 2014b). Thus, new alternatives with increased
therapeutic activity and lesser side effects are desired. This study
suggested that a ferulic acid related compound imparts xanthine
oxidase inhibition and signiﬁcantly reduce formation of uric acid
in human body, indirectly helping to reduce risk of gout by slowing
the XO activity. Further in vivo experiments were needed to iden-
tify whether the active ferulic acid related compounds are potent
inhibitors of XO or not, which are directly correlated to check the
in progress and development of gout and related inﬂammatory
disorders.
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Table  2
In silico pharmacological parameters for bioavailability of ferulic acid related compounds.
Sample Molecular formula Molecular
weight
(g/mol)
Melting point
(◦C)
EHOMO ELUMO HBD HBA Mol. PSA c Log P Solubility Drug
likeness
Drug
score
p-Coumaric acid C9H8O3 164 212 −4.28 −0.65 0 4 56.20 4.45 −4.20 0.53 0.32
Ferulic acid C10H10O4 194 170 −5.52 −0.61 0 5 56.20 4.12 −4.50 0.52 0.40
Caffeic  acid C9H8O4 180 224 −4.25 −0.58 0 4 56.20 4.60 −4.20 0.41 0.38
Sinapic acid C11H12O5 224 204 −5.34 −0.70 0 4 65.5 5.40 −5.34 −0.22 0.35
Alkyl  ferulates C40H70O4 614 96 −9.55 −0.85 0 6 85.5 6.86 −8.50 0.85 0.28
Gallic  acid C7H6O5 170 260 −4.10 −0.60 0 4 55.40 4.11 −4.10 0.55 0.38
Methyl gallate C8H8O5 184 202 −4.61 −0.56 0 4 55.20 4.20 −4.22 −0.32 0.30
I
i
a
a
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cPropyl gallate C10H12O5 212 150 −5.45 
Lauryl gallate C19H30O5 338 98 −6.28 
Stearyl gallate C25H42O5 423 105 −6.85 
nhibition of COX-2 by ferulic acid related compounds
Five ferulic acid related compounds demonstrated COX-2-
nhibiting activity (Fig. 2), among which gallic acid, ferulic acid
nd caffeic acid showed an inhibitor >50% at 100 g/ml. The mech-
nism of anti-inﬂammatory action is assumed to be mediated
hrough the inhibition of COX-1 and COX-2. These enzymes cat-
lyze the biosynthesis of prostaglandin H2 from the arachidonic
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ig. 1. (A) Inhibition ratio (%) and (B) the calculated IC50 of ferulic and gallic acid related
affeic  acid, alkyl ferulates, gallic acid and methyl gallate showed an inhibition >50% at 10−0.55 0 5 60.5 5.10 −4.40 −0.23 0.25
−0.68 0 5 72.5 6.85 −5.30 −0.42 0.22
−0.75 0 6 75.5 6.20 −6.10 −0.65 0.20
acid substrate. The inhibition of COX-1 results in some undesirable
side-effects, whereas COX-2 inhibition provides therapeutic effects
in pain, inﬂammation, cancer, glaucoma, Alzheimer’s and Parkin-
son disease (Blobaum and Marnett, 2007). Therefore, we  intended
to examine the COX-1 and COX-2 inhibitory activity of ferulic acid
related compounds demonstrated on puriﬁed enzymes as a mecha-
nism of its topical anti-inﬂammatory action. Also it was found that
many phenolic compounds such as chlorogenic acid, gallic acid,
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 compounds for inhibition of XO. Six compounds viz.; p-coumaric acid, ferulic acid,
0 g/ml. Allopurinol is a positive control.
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wig. 2. (A) Inhibition ratio (%) and (B) the calculated IC50 of ferulic and gallic acid
nhibiting activity among which ferulic acid, caffeic acid and gallic acid showed an 
osmarinic acid, catechin, hesperidin, hesperetin, lutenolin, narin-
enin, naringin have been demonstrated possessing the inhibitory
ffect for COX-2 expression (Raso et al., 2001; Shen et al., 2008).
hus the result indicates that the ferulic acid related compounds
ay  reduce the inﬂammatory activity by virtue of inhibition of
OX-2 enzyme which provides pro-inﬂammatory activity.
The result indicates that the ferulic acid related compounds may
educe the inﬂammatory activity by virtue of inhibition of xanthine
xidase and COX-2 enzyme which provide pro-inﬂammatory activ-
ty. These compounds might be acts as good source of xanthine
xidase and COX-2 inhibitory agents, but further in vivo and clinical
tudy should be required for their characterization as a drug against
arious diseases and disorders related to activity of xanthine oxi-
ase and COX-2 enzymes. Furthermore the individual the ferulic
cid related compounds can be subjected to optimization so as to
esign and develop a lead anti-inﬂammatory and antigout drug
ith an improved potency. For development of rational drug devel-
pment against XO and cyclooxygenase-2 it is important to check
he structure–activity relationships and other factors of related to
erulic acid compounds such as binding afﬁnity, kinetic parameters
nd changes at active site of these studied enzymes were discussed,
hich is expected for further drug development and design.d compounds for inhibition of COX-2. The ﬁve compounds demonstrated COX-2-
tion >50% at 100 g/ml. DUP-697 is a positive control.
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